RedHill Biopharma Reports 2017 Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Redhill Biopharma (RDHL) PT Lowered to $20 at Roth Capital Following 3Q Release
November 14, 2017 7:08 AM ESTRoth Capital lowered its price target on Redhill Biopharma (NASDAQ: RDHL) to $20.00 (from $27.00) while maintaining a Buy rating following the company's 3Q earnings report. RDHL reported revenues of $1.5M versus estimate of $900K. Lower gross margins offset the revenue upside and gross... More
